Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Zanidatamab Zovodotin
September 12, 2022
ESMO
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Jhaveri et al.
Preclinical
September 9, 2022
World ADC San Diego
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Barnscher et al.
Zanidatamab
August 24, 2022
Future Medicine
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Zanidatamab
June 30, 2022
ESMO World GI Congress
HERIZON-GEA-01: A Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in First-line Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced/metastatic Gastroesophageal Adenocarcinoma (GEA)
Tabernero et al.
Zanidatamab
June 6, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study
Zanidatamab
June 4, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study
Preclinical
May 2, 2022 - May 6, 2022
PEGS
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Petersen et al.
Zanidatamab
April 10, 2021
AACR
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Abraham et al.
Preclinical
March 31, 2022
World ADC London
TOPO1i ADC Platform: From Concept to Pipeline
Zanidatamab
December 8, 2021
SABCS
Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial
Bedard et al.
